Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio By Reuters
© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company’s headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau
PARIS (Reuters) – French drugmaker Sanofi (NASDAQ:) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (NASDAQ:), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson (NYSE:) said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Military training jet crashes in Texas, injuring both pilots
A military training jet crashed Sunday in a Dallas suburb, injuring the two pilots and damaging three homes. Both pilots…
Key data on U.S. J&J, Moderna COVID-19 boosters ‘weeks away,’ Fauci says By Reuters
© Reuters. FILE PHOTO: Top infectious disease expert Dr. Anthony Fauci responds to accusations by Sen. Rand Paul (R-KY) as…